Page last updated: 2024-08-22

zirconium and Androgen-Independent Prostatic Cancer

zirconium has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Aggarwal, R; Chan, E; Chopra, S; Chou, J; Egusa, EA; Evans, MJ; Feng, FY; Foye, A; Hooshdaran, N; Kim, H; Leung, KK; Lim, SA; Sakhamuri, S; Seo, Y; Small, EJ; Sriram, R; Trepka, K; Wang, YH; Wells, JA; Zhang, L; Zhao, N; Zhou, J; Zhu, J	1

Other Studies

1 other study(ies) available for zirconium and Androgen-Independent Prostatic Cancer

Article	Year
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 07-15, Volume: 28, Issue:14 Topics: Animals; Antigens, Neoplasm; Cell Adhesion Molecules; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome; Zirconium	2022

Article

Year

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 07-15, Volume: 28, Issue:14

Topics: Animals; Antigens, Neoplasm; Cell Adhesion Molecules; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome; Zirconium

2022